Realta Life Sciences raised an additional $40 million in the final tranche of its Series A round, bringing total funding to more than $150 million. The company’s program targets hypoxic ischemic encephalopathy (HIE), a severe neonatal condition linked to impaired brain function following oxygen deprivation. The funding extension supports continued advancement of the therapy through development stages and is tied to Realta’s mission-driven investor base and a family-office model. For developers in neonatal neurology, HIE remains an area where effective interventions are limited. The capital also signals investor confidence in the company’s development plan and reinforces ongoing prioritization of high-impact early-life neurologic indications. If successful, Realta’s approach could address a critical care need where timing, delivery, and measurable outcomes matter heavily in clinical execution.